雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究

doi:10.12092/j.issn.1009-2501.2018.03.012

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (3): 313-318.doi: 10.12092/j.issn.1009-2501.2018.03.012

雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究

张洋，陈志康，郭雄，王雯

中南大学湘雅医院肝胆肠外科研究中心结直肠肛门外科，长沙 410008，湖南

收稿日期:2017-09-26 修回日期:2017-12-18 出版日期:2018-03-26 发布日期:2018-03-28
通讯作者: 陈志康，男，博士，主任医师，博士生导师，研究方向：胃肠外科及胃肠道肿瘤的综合治疗。 Tel：0731-89753061 E-mail：25595060@qq.com
作者简介:张洋，男，博士，主治医师，研究方向：肝胆肠微创外科及结直肠癌的综合治疗。 Tel：0731-89753761 E-mail：32163745@qq.com
基金资助:
湖南省自然科学基金（2017JJ3502）

Security observation of intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer

ZHANG Yang, CHEN Zhikang, GUO Xiong, WANG Wen

Colorectal Surgical Department, Hepatobiliary and Enteric Surgery Center, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China

Received:2017-09-26 Revised:2017-12-18 Online:2018-03-26 Published:2018-03-28

摘要/Abstract

摘要：

目的:观察及评估雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗对术后并发症及不良反应、术后恢复、系统毒性等的影响。方法:分析81例结直肠癌患者的临床数据：术中雷替曲塞腹腔灌注组（A组）41例；常规手术对照组（B组）40例。分析比较两组患者术前一般情况、手术时间、术后并发症及不良反应、肠道功能恢复时间、术前及术后3 d的血常规、肝肾功能。结果:两组患者间一般情况比较，差异无统计学意义（P>0.05）。两组患者术后并发症及不良反应、手术时间及肠道功能恢复时间比较，差异均无统计学意义（P>0.05）；两组患者间术前、术后白细胞计数（WBC）、血小板（PLT）、AST、ALT、Cr、BUN比较，差异均无统计学意义（P>0.05）。结论:雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗具有良好的患者耐受性和安全性。

关键词: 结直肠癌, 雷替曲塞, 腹腔镜根治术, 腹腔灌注

Abstract:

AIM: To observe and evaluate the postoperative complication and adverse reaction, postoperative recovery and systemic toxicity of intraperitoneal perfusion chemotherapy with raltitrexed in laparoscopic radical operation for colorectal cancer. METHODS: The clinical data of 81 patients with colorectal cancer were analyzed. Group A underwent laparoscopic radical operation+intraperitoneal perfusion with Raltitrexed; Group B just underwent laparoscopic radical operation. General information, operative time, postoperative complication and adverse reaction, the recovery time of the bowel function, routine blood tests as well as liver and kidney functions before and 3 days after operation between the two groups were evaluated and compared. RESULTS: No statistically significant difference were observed with general information (P>0.05). No statistically significant difference were observed with postoperative complication and adverse reaction, the recovery time of the bowel function and operative time (P>0.05); No statistically significant difference were observed with WBC, PLT, AST, ALT, Cr and BUN before and 3 days after operation (P>0.05). CONCLUSION: Intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer is safe and well tolerated to patient.

Key words: colorectal cancer, raltitrexed, laparoscopic radical operation, intraperitoneal perfusion

中图分类号:

R735.3

张洋，陈志康，郭雄，王雯. 雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究[J]. 中国临床药理学与治疗学, 2018, 23(3): 313-318.

ZHANG Yang, CHEN Zhikang, GUO Xiong, WANG Wen. Security observation of intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 313-318.

参考文献

［1］Zhong YB, Qiu L, Xie PB, et al. Laparoscopic colorectal cancerresection in combination with intraoperative intraperitoneal hyperthermic perfusion chemotherapy［J］. Chin J General Surg, 2015, 24(4): 467-472.
［2］Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer［J］. Ann Surg Oncol, 2013, 20(4): 1088-1092.
［3］Teo MC, Ching Tan GH, Lim C, et al. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center［J］. Asian J Surg, 2015, 38(2): 65-73.
［4］陈伟荣, 李平, 李社方, 等. CD44、NGAL、MIC-1在结直肠癌诊断及远期预后中的应用价值［J］. 疑难病杂志，2017, 16(5): 485-488.
［5］杨东，海栗斌，王钊. 进展期结直肠癌腹腔镜术中5-Fu腹腔冲洗联合缓释置入对手术近远期结局影响的研究［J］. 重庆医学, 2017, 4(46): 1684-1686.
［6］郭锰. 进展期胃癌术后腹腔化疗的临床疗效分析［J］. 中华肿瘤防治杂志, 2011, 5: 374-376.
［7］Nagao S, Kurosaki A, Iwasa N, et al. Intraperitoneal chemotherapy［J］. Nihon Rinsho, 2012, 70 Suppl 4: 610-616.
［8］Papparella A, Nino F, Coppola S, et al. Peritoneal morphological changes due to pneumoperitoneum: the effect of intra-abdominal pressure［J］. Eur J Pediatr Surg, 2014，24(4): 322-327.
［9］Obata S, Goi T, Nakazawa T, et al. Changes in CO2 concentration increase the invasive ability of colon cancer cells［J］. Anti-cancer Res, 2013, 33(5): 1881-1885.
［10］胡林，李昌荣，李红浪. 腹腔镜手术中超声气雾与肿瘤种植转移相关性研究进展［J］.中国实用外科杂志, 2014, 34(4): 372-375.
［11］王斌斌, 刘彩刚, 阿拉腾宝力德, 等. 淋巴结阴性进展期胃癌复发的模式和影响因素的回顾性研究［J］. 中华临床医师杂志, 2010, 4(12): 2526-2529.
［12］徐建军，刘殿明. 雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较［J］. 东南国防医药, 2015, 17(1): 38-39.
［13］Martin S. Treatment of pancreatic exocrine deficiency［J］. World J Surg, 2003, 27(11): 1192-1195．
［14］Kunisaki C, Shimada H, Akiyama H, et al. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis［J］. Hepatogastroenterology, 2006, 53(69): 473-478.
［15］Kim JY, HS Bae. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP)［J］. Gastric Cancer, 2001, 4(1): 27-33.
［16］Yonemura Y, AX De, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study［J］. Hepatogastroenterol, 2001, 48: 1776-1782.
［17］Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy［J］. Anticancer Res, 2002, 22(2): 1329-1336.
［18］Seymour MT, Trigonis L, Finan PJ, et al. A feasibility, pharmacoki-netic and frequency-escalation trial of intraperitoneal chemotherapyin high risk gastrointestinal tract cancer［J］. EJSO, 2008, 34 (4): 403-409.
［19］Xu DZ, Zhao K, Guo LM, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients［J］. PLoS One, 2008, 3(7):e2565.
［20］Laumbacher B, Gu S, Wank R. Prolongation of life by adoptive cell therapy with cascade primed immune cells in four patients with nonsmall cell lung cancer stages IIIB and IV and a pancoast tumor: a case series［J］. J Med Case Rep, 2013, 7(1): 266.
［21］Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitonaeal chemotherapy［J］. Oncologist, 2005, 10: 112-122.
［22］Tsavaris N, Kosmas C, Vadiaka M, et al. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study［J］. Invest New Drugs, 2002, 20(1): 133-136.
［23］Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer［J］. Anti Cancer Drugs, 2014, 25(10): 1122-1128.
［24］张月馨, 常靓, 刘巍. 抗癌药雷替曲塞的研究进展［J］. 临床荟萃, 2011, 21: 1928-1931.
［25］Comandone A, Oliva C, Dal Canton O, et al.［Raltitrexed in colorectal cancer］［J］. Tumori, 2001, 87(1 Suppl 1): S53-54.
［26］Sato KT, Lewandowski RJ, Mulcahy MF, et al.Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival［J］. Radiology, 2008, 247: 507-515.
［27］李如标, 张为民, 高英. 注射用雷替曲塞在晚期实体瘤患者体内的药动学［J］. 中国新药与临床杂志, 2011, 9: 709-712.
［28］臧金林, 周东风. 直肠癌 Dixon 术中应用雷替曲塞的安全性评估［J］. 中国现代普通外科进展, 2016, 19(12): 960-962.
［29］Zhao P, Ding Z. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer［J］. World J Surg Oncol, 2014, 12(1): 1-7.

[1]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[2]	卫真真, 隋华, 姜宇朗, 孙明瑜, 闫化茹, 王子元. 左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 130-137.
[3]	周广琛, 刘怡希, 郑云. 结直肠癌和microRNA：研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 575-587.
[4]	李岩岩, 方骁杰, 尹鑫, 孙曦, 饶春晖. circZNF124通过靶向miR-4262调控结直肠癌SW620细胞增殖、迁移及侵袭的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1231-1239.
[5]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[6]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[7]	王高卿, 江伟, 华永飞. 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 752-756.
[8]	王子元, 孙明瑜. 长链非编码RNA在结直肠癌耐药中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 796-802.
[9]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[10]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[11]	乔大伟，李玉芳，肖云，姜礼双，卜平. 半枝莲抗结直肠癌及其转移机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 332-336.
[12]	白艳，郑晓永，杨雅阁，方立峰. 程序性死亡配体1基因遗传变异对术后结直肠癌患者接受5-FU为基础辅助化疗预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 180-187.
[13]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[14]	胡洋，李智星，王果，朱院山. 长链非编码RNA与结直肠癌耐药的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 456-463.
[15]	李智星，胡洋，王果，朱院山. lncRNA与Wnt/β-catenin通路的相互关系在结直肠癌中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(3): 342-351.

雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究

Security observation of intraperitoneal perfusion chemotherapy with Raltitrexed in laparoscopic radical operation for colorectal cancer

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价